559 related articles for article (PubMed ID: 26470610)
1. New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes.
van der Zee HH; Jemec GB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S23-6. PubMed ID: 26470610
[TBL] [Abstract][Full Text] [Related]
2. Hidradenitis suppurativa in the pediatric population.
Liy-Wong C; Pope E; Lara-Corrales I
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S36-41. PubMed ID: 26470613
[TBL] [Abstract][Full Text] [Related]
3. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
4. Natural history, presentation, and diagnosis of hidradenitis suppurativa.
Micheletti RG
Semin Cutan Med Surg; 2014 Jun; 33(3 Suppl):S51-3. PubMed ID: 25188458
[TBL] [Abstract][Full Text] [Related]
5. Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation.
Zouboulis CC; Del Marmol V; Mrowietz U; Prens EP; Tzellos T; Jemec GB
Dermatology; 2015; 231(2):184-90. PubMed ID: 26139027
[TBL] [Abstract][Full Text] [Related]
6. Interobserver variability of clinical scores in hidradenitis suppurativa is low.
Sartorius K; Killasli H; Heilborn J; Jemec GB; Lapins J; Emtestam L
Br J Dermatol; 2010 Jun; 162(6):1261-8. PubMed ID: 20184581
[TBL] [Abstract][Full Text] [Related]
7. Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems.
Włodarek K; Stefaniak A; Matusiak Ł; Szepietowski JC
Dermatology; 2020; 236(1):8-14. PubMed ID: 31487719
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients.
Join-Lambert O; Coignard-Biehler H; Jais JP; Delage M; Guet-Revillet H; Poirée S; Duchatelet S; Jullien V; Hovnanian A; Lortholary O; Nassif X; Nassif A
J Antimicrob Chemother; 2016 Feb; 71(2):513-20. PubMed ID: 26565016
[TBL] [Abstract][Full Text] [Related]
9. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.
Thorlacius L; Garg A; Riis PT; Nielsen SM; Bettoli V; Ingram JR; Del Marmol V; Matusiak L; Pascual JC; Revuz J; Sartorius K; Tzellos T; van der Zee HH; Zouboulis CC; Saunte DM; Gottlieb AB; Christensen R; Jemec GBE
Br J Dermatol; 2019 Sep; 181(3):483-491. PubMed ID: 30724351
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
11. A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa.
Hessam S; Scholl L; Sand M; Schmitz L; Reitenbach S; Bechara FG
JAMA Dermatol; 2018 Mar; 154(3):330-335. PubMed ID: 29417136
[TBL] [Abstract][Full Text] [Related]
12. Crystallized phenol for sacral hidradenitis suppurativa.
Turan E; Dogru O; Kargin S; Kerimoglu RS; Nazik EE
J Dermatolog Treat; 2021 Mar; 32(2):193-196. PubMed ID: 31259621
[TBL] [Abstract][Full Text] [Related]
13. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
[TBL] [Abstract][Full Text] [Related]
14. AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa.
Chiricozzi A; Faleri S; Franceschini C; Caro RD; Chimenti S; Bianchi L
Wounds; 2015 Oct; 27(10):258-64. PubMed ID: 26479209
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hidradenitis suppurativa with biologic medications.
Lee RA; Eisen DB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
[TBL] [Abstract][Full Text] [Related]
16. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study.
Canoui-Poitrine F; Le Thuaut A; Revuz JE; Viallette C; Gabison G; Poli F; Pouget F; Wolkenstein P; Bastuji-Garin S
J Invest Dermatol; 2013 Jun; 133(6):1506-11. PubMed ID: 23235532
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa.
Join-Lambert O; Coignard H; Jais JP; Guet-Revillet H; Poirée S; Fraitag S; Jullien V; Ribadeau-Dumas F; Thèze J; Le Guern AS; Behillil S; Leflèche A; Berche P; Consigny PH; Lortholary O; Nassif X; Nassif A
Dermatology; 2011 Feb; 222(1):49-58. PubMed ID: 21109728
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
Zouboulis CC; Tzellos T; Kyrgidis A; Jemec GBE; Bechara FG; Giamarellos-Bourboulis EJ; Ingram JR; Kanni T; Karagiannidis I; Martorell A; Matusiak Ł; Pinter A; Prens EP; Presser D; Schneider-Burrus S; von Stebut E; Szepietowski JC; van der Zee HH; Wilden SM; Sabat R;
Br J Dermatol; 2017 Nov; 177(5):1401-1409. PubMed ID: 28636793
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology of hidradenitis suppurativa: An update.
Prens E; Deckers I
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S8-11. PubMed ID: 26470623
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of the severity of hidradenitis suppurativa].
Revuz J
Ann Dermatol Venereol; 2015 Dec; 142(12):729-35. PubMed ID: 26372547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
